Evaluation of High-Sensitivity Cardiac Troponin I in Patients with Acute Myocardial Infarction

Laiba Farooq; Awais Ahmed Uttra; Aurang Zeb; Muhammad Musawir Khan; Nazish Iftikhar

doi:10.66021/pakmcr1008

Authors

Laiba Farooq Department of Biotechnology and Genetic Engineering, Kohat University of Science and Technology Author
Awais Ahmed Uttra Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hat Yai 90110, Thailand & Department of Pharmacy, Obaid Noor Institute of Medical Sciences, Mianwali 42200, Pakistan Author
Aurang Zeb MBBS, FCPS Cardiology, Saidu Teaching Hospital Swat Author
Muhammad Musawir Khan Department of Microbiology, University of Balochistan Author
Nazish Iftikhar Department Pharmacy, University Abasyn University Islamabad campus Author

DOI:

https://doi.org/10.66021/pakmcr1008

Keywords:

Acute Myocardial Infarction, High-Sensitivity Cardiac Troponin I, Diagnostic Accuracy, Roc Curve, Cardiac Biomarkers.

Abstract

Background: Acute myocardial infarction (AMI) is a major global cause of morbidity and death, and prompt treatment depends on a quick diagnosis using high-sensitivity cardiac troponin I (hs-cTnI). Objective: This study's objective was to evaluate hs-cTnI's diagnostic value in individuals with suspected AMI. Methodology: The study was a prospective observational study carried out from March 2024 to February 2025 in the Department of Cardiology, Saidu Teaching Hospital, Swat, and the Department of Pharmacy, Abasyn University Islamabad Campus. All eligible patients with suspected AMI were recruited using consecutive sampling and the levels of hs-cTnI were measured at baseline and 3–6 hours; the final clinical diagnosis was the gold standard for diagnostic accuracy. Data were analysed with the SPSS software version 25. Results

Of the 326 patients, 152 (46.63%) had no AMI and 174 (53.37%) had an AMI diagnosis. The most prevalent symptom (88.65%) was chest discomfort. The most common risk factors were diabetes mellitus (45.40%) and hypertension (53.99%). For hs-cTnI, the corresponding sensitivity, specificity, positive predictive value, negative predictive value, and overall accuracy were 91.95%, 81.58%, 85.11%, 89.86%, and 87.12%. Excellent diagnostic performance was shown by the area under the ROC curve, which was 0.91 (95% CI: 0.88–0.94). AMI patients had considerably higher mean hs-cTnI levels (12.84 ± 4.56 ng/L) than non-AMI patients (2.36 ± 1.18 ng/L, p < 0.001).

Conclusion

Hs-cTnI is a strong discriminator and a reliable early biomarker for the diagnosis of AMI.